Can the MEGX test and serum bile acids improve the prognostic ability of Child - Pugh's score in liver cirrhosis?

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 5, 1999, Pages 559-563

  Testa, Roberto ^a   Valente, Umberto ^b   Risso, Domenico ^b   Caglieris, Sergio ^a   Giannini, Edoardo ^a   Fasoli, Alberto ^a   Botta, Federica ^a   Dardano, Giovanni ^b   Lantieri, Pasquale Bruno ^b   Celle, Guido ^a  

^a Gastroenterology Unit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Child Pugh's score; Liver cirrhosis; Monoethylglycinexylidide; Serum bile acids; Survival

Indexed keywords

BILE ACID; DEETHYLLIDOCAINE; LIDOCAINE; PROTHROMBIN;

ADULT; AGED; ARTICLE; ASCITES; BILE ACID BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SCORING SYSTEM; SURVIVAL;

EID: 0033000012     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199905000-00016     Document Type: Article

References (25)

1. 1 Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981; 1:673-676.
2. 2 Infante-Rivard C, Esnaola S, Villeneuve J-P. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7:660-664.
3. 3 Shaked A, Nunes FA, Olthoff KM, Lucey MR. Assessment of liver function: pre and peri transplant evaluation. Clin Chem 1997; 43:1539-1545.
4. 4 Christensen E. Prognostic models in chronic liver disease: validity, usefulness and future role. J Hepatol 1997; 26:1414-1424.
5. 5 Oellorich M, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, et al. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991; 51:801-806.
6. 6 Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14:1029-1034.
7. 7 Arrigoni A, Gindro T, Aimo G, Cappello N, Meloni A, Benedetti P, et al. Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20:383-387.
8. 8 Jalan R, Hayes PC. Review article: quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9:263-270.
9. 9 Oellerich M, Schutz E, Polzien F, Ringe B, Armstrong VW, Hartmann H, et al. Influence of gender on the monoethylglicinexylidide test in normal subjects and liver donors. Ther Drug Monit 1994; 16:225-231.
10. 10 Orlando R, Palatini P. The effect of age on plasma MEGX concentration. Br J Clin Pharmacol 1997; 44:206-208.
11. 11 Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T, Paumgartner G. Prognostic significance of serum bile acids in cirrhosis. Hepatology 1986; 6:50-53.
12. 12 Testa R, Bindi P, Dagnino F, Grasso A, Bardellini E, Celle G. Inclusion of serum bile acids in Child-Turcotte-Pugh's score can improve grading assessment of alcoholic cirrhosis. Eur J Gastroenterol Hepatol 1992; 4:129-132.
13. 13 Testa R, Borzone S, Risso D, Bardellini E, Caglieris S, Campo N, et al. Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis. Eur J Gastroenterol Hepatol 1993; 5:845-851.
14. 14 Oellerich M, Hartmann H, Ringe B, Burdelski M, Lautz H-U, Pichlmayr R. Assessment of prognosis in transplant candidates by use of Pugh-MEGX score. Transplant Proc 1993; 25:1116-1119.
15. 15 Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V, et al. Long course and prognostic factors of virus induced cirrhosis of the liver. Am J Gastroenterol 1997; 92:66-72.
16. 16 Adler M, Verset D, Bouhdid H, Bourgeois N, Gulbis B, Le Moine O, et al. Prognostic evaluation of patients with parenchymal cirrhosis. J Hepatol 1997; 26:642-649.
17. 17 Merkel C, Bolognesi M, Bellon S, Bianco S, Honish B, Lampe H, Angeli P, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33:836-842.
18. 18 Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test and ICG clearance in patients with cirrhosis. Dig Dis Sci 1991; 36:1197-1203.
19. 19 Shiffman ML, Fisher RA, Sanyal AJ, Edinboro LE, Luketic VA, Purdum PP III, et al. Hepatic lidocaine metabolism and complication of cirrhosis. Transplantation 1993; 55:830-834.
20. 20 Luketic VA, Shiffman ML, Fisher LA, Sanyal AJ, Purdum PP III, Posner MP. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation. Transplant Proc 1993; 25:1072-1074.
21. 21 Meyer-Wiss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993; 19:133-139.
22. 22 Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al. Measuring lidocaine metabolite - monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19:140-147.
23. 23 Shiffman ML, Luketic VA, Sanyal AJ, Ducworth F, Purdum PP III, Contos MJ, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 1994; 19:933-940.
24. 24 Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinetics 1978; 3:177-201.
25. 25 Reichel C, Nacke A, Sudhop T, Wienkoop G, Lüers C, Hahn C, et al. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. Hepatology 1997; 25:1323-1327.